PROCEPT BioRobotics missed on both lines in the third quarter. It reported a loss of $0.46 per share against a consensus loss of $0.39, a 17.9% negative surprise. Revenue of $98.29 million rose 18.0% year over year but came in 1.8% below the $100.07 million consensus. The loss also widened from $0.38 a year earlier, so earnings fell 21.1% year over year.

Management reaffirmed every full-year target: revenue of $390 million to $410 million, U.S. procedures of 54,000 to 56,000, gross margin of about 65%, and an adjusted EBITDA loss of $30 million to $35 million. That reaffirmation is the headline the company wants investors to see. The central tension is that the guidance now rests almost entirely on a fourth-quarter inflection that the third quarter did little to demonstrate.

The quality of the quarter is uneven. U.S. handpiece and consumable revenue was the clear bright spot, up 21% to $53.9 million. That is a sharp acceleration from roughly 12% to 13% growth in the first half. The gain came from two sources:

• The handpiece-to-procedure ratio rose to 106% from 98% in Q2.
• Handpiece ASP climbed 12% year over year to about $3,570.

Gross margin improved to 66% from 65%. International revenue hit a record $12.5 million, up 32%.

Other lines were weaker. U.S. system revenue was flat at $24.7 million, and three systems had revenue deferred pending payment. Operating expenses rose roughly 20% to $92.5 million, and interest income declined. As a result, the GAAP net loss grew to $26.5 million from $21.4 million. Adjusted EBITDA was a $9.8 million loss, worse than the $7.4 million loss a year ago but better than the $11.3 million loss in Q2 and $18.1 million in Q1.

The operating trends on the call explain the miss. U.S. procedures of about 13,400 grew 22% year over year but were essentially flat with Q2's 13,100. Total revenue growth has eased each quarter, from 20% to 19% to 18%.

The procedure outlook has been cut repeatedly. Management originally talked about 60,000 to 64,000 procedures, cut the range to 54,000 to 56,000 in Q2, and now points to roughly 54,000, the low end. Even that requires 14% to 29% sequential procedure growth in Q4. Revenue guidance likewise implies a substantial step-up from Q3's run rate.

Greenfield placements also slipped. About 42 of the 62 HYDROS systems delivered were new accounts, down from 50 in Q2, which management attributed to timing. Other headwinds include persistent AquaBeam utilization declines, as some cases are deferred until accounts move to HYDROS. Procedure visibility is also falling as more cases run autonomously without a rep present.

The offset is a replacement cycle that is turning into a real growth engine. Replacement guidance rose to 50 to 60 units at roughly $315,000 each, up from about 40 in Q2 and just 5 to 10 at the start of the year. Thirty-six replacements have been completed year to date.

The case for the upgrades is utilization. HYDROS accounts run more than 35% more procedures than AquaBeam accounts, and HYDROS should exceed 60% of the installed base exiting 2026. New-system ASP held near $495,000, above the outlook given in Q2. Launch-team coverage reached about 70% of placements, up from 40% in Q2.

On profitability, the guidance implies Q4 adjusted EBITDA of positive $3 million to $9 million. Bears have legitimate ammunition here. Q4 gross margin is guided to about 65%, below earlier talk of a 66%-plus exit rate. The initial 2027 base case of roughly 20% revenue growth is a clear deceleration from 2026's guided 27% to 33%, even with promised operating leverage. Cash also declined to $221.4 million from about $289.5 million at year-end.

The biggest longer-term catalyst remains WATER IV, the randomized trial of Aquablation versus radical prostatectomy in prostate cancer. Its primary endpoint is slated for the AUA meeting in May 2027.

The market setup is more complicated than the miss implies. Investor sentiment remained negative but improved meaningfully heading into the report, rising from -0.478 to -0.283. Shares closed at $20.17 on the pre-report snapshot. That is up 15.5% from the $17.46 opening after the August report and 20.5% above the October 1 low of $16.74. However, the stock remained 13.3% below its 200-day moving average of $23.25 and 12.0% below the post-report high of $22.93 set in August.

Investors had partially rebuilt expectations off the lows without restoring confidence in the trend. The Earnings Whispers trend readings are mixed: sequential growth is positive, but AVWAP remains negative.

The bottom line is that PROCEPT delivered a quarter of better consumable economics and a faster HYDROS upgrade cycle, wrapped around a headline miss and stalled procedure volume. Reaffirmed guidance keeps the 2026 story intact on paper. But it depends on a fourth-quarter reacceleration in procedures and a swing to positive adjusted EBITDA, and the third quarter provided little direct evidence for either. Until procedures move decisively off the 13,000 plateau, the replacement cycle and WATER IV are carrying more of the investment case than the core growth engine.